Antiretroviral therapy coverage in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)
Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD): Antiretroviral therapy coverage was 26.5% in 2024. ◆ Volatile
Antiretroviral therapy coverage in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD), 2000–2024
Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of people living with HIV.
Analysis
Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) recorded 26.5% for antiretroviral therapy coverage in 2024. That is the highest value across all 25 years on record.
That represents a change of up 6.1% on the previous year and up 123.9% over ten years.
Over the whole period, antiretroviral therapy coverage in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) peaked at 26.5% in 2024 and was at its lowest, 1.0%, in 2000.
That places Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) 22nd out of 23 groups with data for 2024, putting it in the bottom quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Antiretroviral therapy coverage in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD), year by year
| Year | % of people living with HIV | Change |
|---|---|---|
| 2000 | 1.0% | — |
| 2001 | 1.2% | +19.4% |
| 2002 | 1.4% | +18.8% |
| 2003 | 2.3% | +66.9% |
| 2004 | 3.2% | +36.7% |
| 2005 | 3.6% | +13.9% |
| 2006 | 4.4% | +19.7% |
| 2007 | 4.6% | +4.8% |
| 2008 | 5.6% | +22.9% |
| 2009 | 6.2% | +10.8% |
| 2010 | 7.0% | +13.0% |
| 2011 | 7.4% | +5.8% |
| 2012 | 8.9% | +20.2% |
| 2013 | 9.9% | +10.5% |
| 2014 | 11.8% | +19.7% |
| 2015 | 12.6% | +7.0% |
| 2016 | 14.6% | +15.7% |
| 2017 | 16.7% | +14.3% |
| 2018 | 18.5% | +10.8% |
| 2019 | 20.4% | +10.2% |
| 2020 | 20.3% | -0.7% |
| 2021 | 21.2% | +4.6% |
| 2022 | 22.7% | +7.2% |
| 2023 | 24.9% | +9.8% |
| 2024 | 26.5% | +6.1% |
Biggest year-on-year movements
Years where Antiretroviral therapy coverage in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2003 | +66.9% | 1.4% | 2.3% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 3.4% | 1.0% | 6.2% | 10 |
| 2010s | 12.8% | 7.0% | 20.4% | 10 |
| 2020s | 23.1% | 20.3% | 26.5% | 5 |
Countries ranked near Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)
More health data for Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)
- Population ages 35-39, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, male, annual growth rate 3.1 % change on previous year (2025)
- Population ages 40-44, female, per capita 0.0305 units per person (2025)
- Population ages 40-44, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, female, annual growth rate 3.2 % change on previous year (2025)
- Population ages 35-39, male, per capita 0.0351 units per person (2025)
- Population ages 35-39, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, male, annual growth rate 1.48 % change on previous year (2025)
- Population ages 35-39, female, per capita 0.0341 units per person (2025)
- Population ages 30-34, female, annual growth rate 0.471 % change on previous year (2025)
All data for Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) →
Frequently asked questions
- What is antiretroviral therapy coverage in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- Antiretroviral therapy coverage in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) was 26.5% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
- What is the highest antiretroviral therapy coverage recorded in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- The highest recorded value was 26.5% in 2024.
- What is the lowest antiretroviral therapy coverage recorded in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- The lowest recorded value was 1.0% in 2000.
- How does Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) rank for antiretroviral therapy coverage?
- Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) ranks 22nd out of 23 groups with data for 2024.
- Is antiretroviral therapy coverage rising or falling in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- Over the last ten years it is up 123.9%. The long-run trend across the full record is volatile.
- Where does this Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) data come from?
- The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage (% of people living with HIV). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.